Dynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, ...

Results from the first part of a Phase I/II trial (NCT06569823) showed that Z-1018 generated immune responses comparable to ...

Dynavax Technologies Corporation (NASDAQ:DVAX) surged 8% Thursday following the announcement of encouraging topline data from ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

A study published this week in the peer-reviewed journal Scientific Reports examined the long-term impacts of having shingles ...

One of the goals of the Insurance Institute for Business and Home Safety is to make homes and commercial buildings stronger.

Shingles—also known as herpes zoster—is caused by the varicella-zoster virus, the same one that causes chickenpox. If you had that malady as a kid, you’re at risk for a case of shingles ...

Shingles will strike 1 in 3 Americans during their lifetimes — most between ages 60 and 70. Folks in their 60s get shingles at roughly twice the rate as folks in their 50s, reports the CDC.

Although shingles vaccination rates have inched upward in recent years, only a third of adults who were 60 or older in 2016 had received the Zostavax vaccine, the CDC says.